Published by Iain Gilbert on 21st May 2018
(Sharecast News) - Commercial biotechnology company Allergy Therapeutics has seen "highly positive" top-line results from a recent phase two dose-ranging study on its grass-pollen induced seasonal allergic rhinitis drug.
URL: http://www.digitallook.com/dl/news/story/27493299/...